MX378282B - Forma cristalina del inhibidor del receptor androgenico y metodo de preparacion de la misma. - Google Patents
Forma cristalina del inhibidor del receptor androgenico y metodo de preparacion de la misma.Info
- Publication number
- MX378282B MX378282B MX2018002759A MX2018002759A MX378282B MX 378282 B MX378282 B MX 378282B MX 2018002759 A MX2018002759 A MX 2018002759A MX 2018002759 A MX2018002759 A MX 2018002759A MX 378282 B MX378282 B MX 378282B
- Authority
- MX
- Mexico
- Prior art keywords
- crystal
- compound
- formula
- androgen receptor
- receptor inhibitor
- Prior art date
Links
- 102000001307 androgen receptors Human genes 0.000 title abstract 2
- 108010080146 androgen receptors Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003960 organic solvent Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 239000012046 mixed solvent Substances 0.000 abstract 1
- 150000002825 nitriles Chemical class 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan una forma cristalina de un inhibidor del receptor androgénico, y un método de preparación de la misma. En términos particulares, se proporcionan un cristal tipo I de (S)-4-(3-(4-(2,3-dihidroxipropoxi)fenil)-4,4-dimetil-5-carbonil-2-tioimidazolin-1-il)-2-(trifluorometil)benzonitrilo (un compuesto de la fórmula (I)) y un método de preparación del mismo, en donde el método comprende: 1) se agrega cualquier forma cristalina o forma amorfa del compuesto como se muestra por la fórmula (I), a una cantidad adecuada de un solvente orgánico, se calienta y se disuelve hasta que esté transparente, seguido por enfriamiento y cristalización, en donde el solvente orgánico se selecciona a partir de cualquiera de ésteres, cetonas, nitrilos y éteres que tienen 5 o menos átomos de carbono, o un solvente mixto del mismo; y 2) el cristal se filtra, lava y seca. El cristal tipo I obtenido del compuesto de la fórmula (I) tiene una buena estabilidad química y estabilidad de su forma cristalina, y el solvente de cristalización utilizado tiene una baja toxicidad y poca formación de residuos, y se puede utilizar mejor en tratamientos clínicos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510574141 | 2015-09-10 | ||
| CN201610073458 | 2016-02-02 | ||
| PCT/CN2016/096381 WO2017041622A1 (zh) | 2015-09-10 | 2016-08-23 | 一种雄性激素受体抑制剂的结晶形式及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018002759A MX2018002759A (es) | 2018-08-01 |
| MX378282B true MX378282B (es) | 2025-03-10 |
Family
ID=58240573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002759A MX378282B (es) | 2015-09-10 | 2016-08-23 | Forma cristalina del inhibidor del receptor androgenico y metodo de preparacion de la misma. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10150739B2 (es) |
| EP (1) | EP3348546B1 (es) |
| JP (1) | JP6843116B2 (es) |
| KR (1) | KR20180048939A (es) |
| CN (1) | CN107001284B (es) |
| AU (1) | AU2016318700B2 (es) |
| BR (1) | BR112018003258A2 (es) |
| CA (1) | CA2996674A1 (es) |
| CY (1) | CY1123027T1 (es) |
| DK (1) | DK3348546T3 (es) |
| ES (1) | ES2794568T3 (es) |
| HR (1) | HRP20200852T1 (es) |
| HU (1) | HUE050459T2 (es) |
| LT (1) | LT3348546T (es) |
| MX (1) | MX378282B (es) |
| PL (1) | PL3348546T3 (es) |
| PT (1) | PT3348546T (es) |
| RS (1) | RS60448B1 (es) |
| RU (1) | RU2018109121A (es) |
| SI (1) | SI3348546T1 (es) |
| SM (1) | SMT202000258T1 (es) |
| TW (1) | TWI708764B (es) |
| WO (1) | WO2017041622A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3348546T3 (da) | 2015-09-10 | 2020-07-06 | Jiangsu Hengrui Medicine Co | Krystallinsk form af androgenreceptorinhibitor og fremgangsmåde til fremstilling deraf |
| CN112174895B (zh) * | 2017-12-13 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的晶型及其制备方法 |
| CA3251059A1 (en) | 2022-05-02 | 2023-11-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions, systems and methods for modulating a target gene |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070106969A (ko) | 2004-09-09 | 2007-11-06 | 추가이 세이야쿠 가부시키가이샤 | 신규 이미다졸리딘 유도체 및 그 용도 |
| NZ564223A (en) | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| EP2416657A4 (en) * | 2009-04-09 | 2012-09-05 | Medivation Prostate Therapeutics Inc | COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF |
| SI2894151T1 (sl) * | 2012-09-04 | 2021-01-29 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini |
| KR20150053963A (ko) * | 2012-09-11 | 2015-05-19 | 닥터 레디스 레보러터리즈 리미티드 | 엔잘루타마이드 다형태 및 그의 제조 |
| CN104356068A (zh) * | 2014-10-30 | 2015-02-18 | 杭州新博思生物医药有限公司 | 恩杂鲁胺新晶型及其制备方法 |
| DK3348546T3 (da) | 2015-09-10 | 2020-07-06 | Jiangsu Hengrui Medicine Co | Krystallinsk form af androgenreceptorinhibitor og fremgangsmåde til fremstilling deraf |
-
2016
- 2016-08-23 DK DK16843560.0T patent/DK3348546T3/da active
- 2016-08-23 PT PT168435600T patent/PT3348546T/pt unknown
- 2016-08-23 LT LTEP16843560.0T patent/LT3348546T/lt unknown
- 2016-08-23 MX MX2018002759A patent/MX378282B/es unknown
- 2016-08-23 AU AU2016318700A patent/AU2016318700B2/en not_active Ceased
- 2016-08-23 HU HUE16843560A patent/HUE050459T2/hu unknown
- 2016-08-23 SM SM20200258T patent/SMT202000258T1/it unknown
- 2016-08-23 KR KR1020187009184A patent/KR20180048939A/ko not_active Ceased
- 2016-08-23 CN CN201680003850.4A patent/CN107001284B/zh active Active
- 2016-08-23 JP JP2018508712A patent/JP6843116B2/ja not_active Expired - Fee Related
- 2016-08-23 WO PCT/CN2016/096381 patent/WO2017041622A1/zh not_active Ceased
- 2016-08-23 EP EP16843560.0A patent/EP3348546B1/en active Active
- 2016-08-23 BR BR112018003258-1A patent/BR112018003258A2/pt not_active Application Discontinuation
- 2016-08-23 US US15/757,652 patent/US10150739B2/en active Active
- 2016-08-23 RU RU2018109121A patent/RU2018109121A/ru unknown
- 2016-08-23 CA CA2996674A patent/CA2996674A1/en active Pending
- 2016-08-23 HR HRP20200852TT patent/HRP20200852T1/hr unknown
- 2016-08-23 PL PL16843560T patent/PL3348546T3/pl unknown
- 2016-08-23 RS RS20200617A patent/RS60448B1/sr unknown
- 2016-08-23 SI SI201630801T patent/SI3348546T1/sl unknown
- 2016-08-23 ES ES16843560T patent/ES2794568T3/es active Active
- 2016-09-07 TW TW105128891A patent/TWI708764B/zh not_active IP Right Cessation
-
2020
- 2020-06-09 CY CY20201100522T patent/CY1123027T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2794568T3 (es) | 2020-11-18 |
| JP2018526364A (ja) | 2018-09-13 |
| RS60448B1 (sr) | 2020-07-31 |
| RU2018109121A3 (es) | 2019-12-04 |
| WO2017041622A1 (zh) | 2017-03-16 |
| PL3348546T3 (pl) | 2020-09-21 |
| AU2016318700A1 (en) | 2018-04-05 |
| BR112018003258A2 (pt) | 2018-09-25 |
| CY1123027T1 (el) | 2021-10-29 |
| AU2016318700B2 (en) | 2020-05-07 |
| SMT202000258T1 (it) | 2020-07-08 |
| KR20180048939A (ko) | 2018-05-10 |
| PT3348546T (pt) | 2020-05-29 |
| HRP20200852T1 (hr) | 2020-08-21 |
| DK3348546T3 (da) | 2020-07-06 |
| CN107001284B (zh) | 2019-11-22 |
| CN107001284A (zh) | 2017-08-01 |
| HUE050459T2 (hu) | 2020-12-28 |
| SI3348546T1 (sl) | 2020-09-30 |
| CA2996674A1 (en) | 2017-03-16 |
| EP3348546A1 (en) | 2018-07-18 |
| US20180244628A1 (en) | 2018-08-30 |
| LT3348546T (lt) | 2020-07-27 |
| MX2018002759A (es) | 2018-08-01 |
| US10150739B2 (en) | 2018-12-11 |
| RU2018109121A (ru) | 2019-10-10 |
| JP6843116B2 (ja) | 2021-03-17 |
| EP3348546A4 (en) | 2019-03-27 |
| TWI708764B (zh) | 2020-11-01 |
| EP3348546B1 (en) | 2020-04-29 |
| TW201713628A (zh) | 2017-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210507T1 (hr) | Supstituirani 5-fluoro-1h-pirazolopiridini u kristalnom obliku | |
| JOP20250289A1 (ar) | صور بلورية جديدة | |
| MX2015010837A (es) | Compuestos de antranilamida, sus mezclas y el uso de los mismos como pesticidas. | |
| MX392440B (es) | Inhibidores de tirosina quinasa de bazo (syk). | |
| RU2016144197A (ru) | Фунгицидные производные n'-[2-метил-6[2-алкоксиэтокси]-3-пиридил]-n-алкилформамидина для применения в сельском хозяйстве | |
| EA201270676A1 (ru) | Полиморфная, кристаллическая и мезофазная формы 2-(5-бром-4-(4-циклопропилнафталинил-1-ил)-4н-1,2,4-триазол-3- илтио)ацетата натрия и их применение | |
| EA201291236A1 (ru) | Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10 | |
| CL2018000241A1 (es) | Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il) propanoico sustituido. | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| EA201690094A1 (ru) | Ингибиторы syk | |
| EA201590023A1 (ru) | Новые 4-замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса | |
| EA201590548A1 (ru) | Кристаллические формы ингибитора фактора xia | |
| PE20141191A1 (es) | Compuestos como inhibidores de bace | |
| WO2014147021A3 (en) | 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders | |
| HRP20191431T1 (hr) | Postupak za pripravu (4s)-4-(4-cijano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1-6- naftiridin-3-karboksamida i njegovo pročišćavanje za uporabu kao aktivni farmaceutski pripravak | |
| CY1123027T1 (el) | Κρυσταλλικη μορφη αναστολεα υποδοχεα ανδρογονων και μεθοδος παρασκευης αυτου | |
| MX2016008536A (es) | Derivados de fluoro-naftilo. | |
| PE20151748A1 (es) | Inhibidores de bace1 | |
| EA201891023A1 (ru) | Новая соль абексиностата, соответствующая кристаллическая форма, способ ее получения и содержащие ее фармацевтические композиции | |
| MX2012000177A (es) | 2-carboxamida-cicloamino-ureas sustituidas. | |
| MX2021011971A (es) | Proceso para preparar cicloserinas sustituidas. | |
| JP2016529315A5 (es) | ||
| RU2016107830A (ru) | Производное замещенного пиразолилпиразола и его применение в качестве гербицида | |
| BR112017018580A2 (pt) | p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal | |
| PE20181002A1 (es) | Derivados del acido 5-(n- bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana |